Prevencio Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 2

Prevencio General Information

Description

Developer of multi-proteomic biomarkers designed to transform blood tests for cardiovascular disease. The company's biomarkers employ artificial intelligence to interrogate well-characterized clinical data sets to produce novel, multi-protein, algorithmically-scored tests, enabling clinicians to assess pre-drug or post-drug effects on a composite of heart attack, stroke, and cardiac death.

Contact Information

Website
www.prevenciomed.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 6424 Lake Washington Boulevard North East
  • Suite 13
  • Kirkland, WA 98033
  • United States
+1 (425)
Primary Industry
Biotechnology
Other Industries
Other Healthcare Services
Drug Discovery
Vertical(s)
Artificial Intelligence & Machine Learning, Life Sciences
Corporate Office
  • 6424 Lake Washington Boulevard North East
  • Suite 13
  • Kirkland, WA 98033
  • United States
+1 (425)

Prevencio Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Prevencio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Accelerator/Incubator 29-May-2024 Completed Generating Revenue
4. Later Stage VC (Series B1) 16-Mar-2022 Completed Generating Revenue
3. Accelerator/Incubator 01-Oct-2019 Completed Clinical Trials - General
2. Later Stage VC (Series B) 30-Jun-2016 $4.8M $6.8M Completed Clinical Trials - General
1. Later Stage VC (Series A) 30-Dec-2013 $2M $2M Completed Clinical Trials - General
To view Prevencio’s complete valuation and funding history, request access »

Prevencio Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B-0
Series B1
Series B 5,562,744 $0.000100 8% $1 $1 1x $1 21.76%
Series A 3,578,826 $0.000100 8% $0.9 $0.9 1x $0.9 14%
To view Prevencio’s complete cap table history, request access »

Prevencio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of multi-proteomic biomarkers designed to transform blood tests for cardiovascular disease. The company's biom
Biotechnology
Kirkland, WA
10 As of 2024

Austin, TX
 

Irving, TX
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Prevencio Competitors (10)

One of Prevencio’s 10 competitors is Natera, a Formerly VC-backed company based in Austin, TX.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Natera Formerly VC-backed Austin, TX
Caris Life Sciences Private Equity-Backed Irving, TX
Ambry Genetics Private Equity-Backed Aliso Viejo, CA
GRAIL Formerly VC-backed Menlo Park, CA
Positive Biosciences Corporation Mumbai, India
You’re viewing 5 of 10 competitors. Get the full list »

Prevencio Patents

  • 22

    Total Documents Applications and Grants

  • Total Patents Families

  • 7

    Granted

  • 9

    Pending

  • Expiring in next 12 mo

Prevencio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220178946-A1 Prognostic and diagnostic methods for risk of acute kidney injury Pending 02-Nov-2018
EP-3704491-A1 Diagnostic and prognostic methods for peripheral arterial diseases, aortic stenosis, and outcomes Pending 02-Nov-2017
CA-3081752-A1 Diagnostic and prognostic methods for peripheral arterial diseases, aortic stenosis, and outcomes Pending 02-Nov-2017
EP-3704491-A4 Diagnostic and prognostic methods for peripheral arterial diseases, aortic stenosis, and outcomes Pending 02-Nov-2017
US-20220229071-A1 Diagnostic and prognostic methods for peripheral arterial diseases, aortic stenosis, and outcomes Pending 02-Nov-2017 G01N33/6893
To view Prevencio’s complete patent history, request access »

Prevencio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Prevencio Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
MedTech Innovator Accelerator/Incubator
G4A Accelerator/Incubator Minority
To view Prevencio’s complete investors history, request access »

Ready to get started?

Request a free trial

Prevencio FAQs

  • When was Prevencio founded?

    Prevencio was founded in 2006.

  • Where is Prevencio headquartered?

    Prevencio is headquartered in Kirkland, WA.

  • What is the size of Prevencio?

    Prevencio has 10 total employees.

  • What industry is Prevencio in?

    Prevencio’s primary industry is Biotechnology.

  • Is Prevencio a private or public company?

    Prevencio is a Private company.

  • What is Prevencio’s current revenue?

    The current revenue for Prevencio is .

  • How much funding has Prevencio raised over time?

    Prevencio has raised $15.2M.

  • Who are Prevencio’s investors?

    MedTech Innovator and G4A have invested in Prevencio.

  • Who are Prevencio’s competitors?

    Natera, Caris Life Sciences, Ambry Genetics, GRAIL, and Positive Biosciences are some of the 10 competitors of Prevencio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »